Daiichi Sankyo invests $150 million to establish a new antibody-drug conjugate manufacturing facility in Shanghai by 2030, ...

In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

The new 1.1 billion-yuan ($152 million) production facility in Shanghai will make antibody-drug conjugates, which use ...

Daiichi Sankyo Company is making significant strides in the pharmaceutical industry, evidenced by its financial growth and strategic collaborations, such as with Merck on MK-6070. The company is set ...

Toshinori Agatsuma, head of research at Daiichi Sankyo, has died. He led development of ADC technology behind breast cancer ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...

AstraZeneca's (NASDAQ:AZN) blockbuster cancer medication, Enhertu, developed with Japanese pharma giant Daiichi Sankyo (OTCPK ...

The UK’s National Institute for Health and Care Excellence (NICE) has once again rejected Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu (trastuzumab deruxtecan), marking the third ...

Enhertu is an antibody-drug conjugate (ADC) designed to treat patients with certain types of breast cancer. Credit: Dikushin Dmitry via Shutterstock. The UK’s National Institute for Health and ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s ENHERTU that showed clinically meaningful responses across a broad range of tumorsENHERTU now has... BASKING RIDGE ...